Skip to content

Radioprotective effects of parthenolide lotion against skin injury caused by radiation in people with head and neck cancer

Radioprotective effects of parthenolide lotion against skin injury caused by radiation in people with head and neck cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12625000456459
Acronym
REPAIR-1
Enrollment
1
Registered
2025-05-15
Start date
2025-03-31
Completion date
2025-12-19
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Who is it for? You may be eligible for this study if you are a male or female, aged 18 or over, and diagnosed with locally advanced cancer of the head/neck, scheduled to received equal bilateral radiation+/-chemotherapy (cisplatin/5FU). Study details Participants will be given the skin lotion with 1%parthenolide, applied to one side of the head/neck, with the comparator (placebo) applied to the other side. [Describe what is involved for participants] During and after the intervention, participants will be assessed for radiation induced dermatitis (RID) using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and Radiation-Inducted Skin Reaction Assessment Scale (RISRAS tool) by reviewing of medical data. Skin samples will also be collected from willing participants using a non-invasive tape method which just collects the top layer of cells. This will be performed at baseline and 3 weeks into treatment. It is hoped that this research will demonstrate the effectiveness of a parthenolide-based skin cream in a safe and evidence-based solution to protect patients' skin during radiotherapy.

Interventions

Both the intervention and control lotion are formulated with a base solution comprised of Coconut Water (from freeze-dried coconut powder); Hickory Bark Extract; Lactic Acid, Glycerin, Saccharide Isomerate, Jojoba & Esters. Intervention: Base lotion with 1% parthenolide. Rationale for parthenolide concentration: In vitro dosing of radiation in petri dishes has shown radiation protection of normal cells is achieved with 3 to 10 µM which equates to approximately 1% solution. In vivo experimen

Both the intervention and control lotion are formulated with a base solution comprised of Coconut Water (from freeze-dried coconut powder); Hickory Bark Extract; Lactic Acid, Glycerin, Saccharide Isomerate, Jojoba & Esters. Intervention: Base lotion with 1% parthenolide. Rationale for parthenolide concentration: In vitro dosing of radiation in petri dishes has shown radiation protection of normal cells is achieved with 3 to 10 µM which equates to approximately 1% solution. In vivo experiments noted serum levels of 3 to 10 µM exposure was associated with benefit. Therefore the concentration of parthenolide will be 1%. Amount to be applied: 8 pumps before and after radiation, applied in the radiation unit under supervision by a nurse. Frequency of application: Twice daily (before and after radiation dose) for 6-7 weeks (depending on cycle length, all participants to receive >50Gy radiation to both sides of the neck/face) NO changes to radiation dosing will be implemented by the study team. Changes are only permitted by the treating oncologist. Adherence: Adherence is measured daily, with an adherence log completed by the nurse on duty to confirm application. If application is missed, a reason explaining why is documented. Quality assurance: The lotion will be tested monthly to ensure parthenolide is stable in the lotion. Randomisation of the lotion: The study is non-randomised, with all participants receiving BOTH the intervention and control lotion. The study is double blind, with the intervention and. control lotions labelled LEFT and RIGHT. Nobody in the study (with the exception of the unblinded monitor) knows which lotion is which. The LEFT is always applied to the LEFT side and the RIGHT lotion is always applied to the RIGHT side.

Sponsors

Central Adelaide Local Health Network (CALHN)
Lead SponsorGovernment body

Study design

Allocation
Non-randomised trial
Intervention model
Other
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult (> or = to 18 years) 2. Diagnosed with locally advanced cancer of the head/neck 3. Scheduled to receive equal bilateral radiation + cisplatin/5FU (definitive or adjuvant) 4. Able to provide written informed consent and follow all clinical trial related procedures (translator to be provided for people of culturally and linguistically diverse (CALD) backgrounds)

Exclusion criteria

1. ECOG score >1 2. Life expectancy <6 months as determined by treating clinician 3. Pregnant or lactating 4. History of dermatitis, psoriasis, allergies to any of the ingredients of the lotion or parthenolide or feverfew 5. Skin reaction to test doses of PTL lotion during screening 6. Involved in another trial that may compromise results/interpretation (decided as discretion of treating clinician) 7. Persistent wounds or pathologies related to prior surgery (decided at discretion of treating clinician)

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026